Discover
HLXB
Helix Acquisition Corp. II
9.90
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | ||
| 1y |
9.60
day range
10.09
10.03
52 week range
10.99
| Open | 10.09 | Prev Close | 9.90 | Low | 9.60 | High | 10.09 | Mkt Cap | 253.90M |
| Vol | 127.16K | Avg Vol | 11.37K | EPS | 0.24 | P/E | 45.00 | Forward P/E | N/A |
| Beta | -0.14 | Short Ratio | 0.46 | Inst. Own | 86.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 10.50 | 200-d Avg | 10.37 | 1yr Est | 0.00 |
HLXB News
globenewswire.com
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three cl
globenewswire.com
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tum
globenewswire.com
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection wi
BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”)
globenewswire.com
Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registratio
Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO
businesswire.com
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination
SOUTH SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics (“